Millendo Therapeutics
Millendo Therapeutics is a pre-commercial, publicly traded biopharmaceutical company (NASDAQ: MLND) based in Ann Arbor, Michigan, that develops novel treatments for endocrine and rare diseases and expanded into fertility via its 2018 OvaScience acquisition, serving patients with endocrine disorders.
- Company typePrivate
- Founded2011
- HeadquartersAnn Arbor, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Millendo Therapeutics firmographics
Firmographics- Name
- Millendo Therapeutics
- Website
- https://millendo.com
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 11–50 employees
- Short description
- Millendo Therapeutics is a pre-commercial, publicly traded biopharmaceutical company (NASDAQ: MLND) based in Ann Arbor, Michigan, that develops novel treatments for endocrine and rare diseases and expanded into fertility via its 2018 OvaScience acquisition, serving patients with endocrine disorders.
- Ownership category
- akta.pro rank
Millendo Therapeutics industry classification
Industry- Product category
- Endocrine Disease Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)
- akta.pro secondary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Millendo Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Ann Arbor
- HQ country
- United States
- HQ region
- North America
Markets served
Millendo Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Millendo Therapeutics product offering
Product offeringCore offering
Millendo Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for endocrine diseases, with a particular focus on rare and underserved conditions such as adrenocortical carcinoma. The company has historically pursued drug candidates targeting endocrine disorders through its own pipeline development and corporate transactions.
Differentiator
Problem solved
Functional benefit
Products and services
- Endocrine disease drug candidates
- Adrenocortical carcinoma therapeutic candidate
Companies that use Millendo Therapeutics
Customer profileIdeal customer profiles1 record
Millendo Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Millendo Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Millendo Therapeutics competitors and assessment
Company assessmentDirect peers
- Corcept Therapeutics: Specialist endocrine company commercializing Korlym for Cushing's syndrome — a benchmark rare-endocrine commercial-stage peer for any company in the Cushing's / cortisol space Millendo historically targeted.
- Soleno Therapeutics: Small-cap rare-disease biotech focused on Prader-Willi syndrome and other rare endocrine/metabolic disorders — comparable in size, public-market status, and orphan-endocrine orientation.
- Crinetics Pharmaceuticals: Clinical-stage biopharma developing oral therapeutics for rare endocrine diseases, including acromegaly and Cushing's syndrome — directly overlapping with Millendo's historical rare-endocrine focus.
- Strongbridge Biopharma: Pre-merger small-cap rare endocrine company (Keveyis, Recorlev for Cushing's) — a structural comp to Millendo as a similarly sized rare-endocrine specialist that ultimately reached a strategic exit.
- Spruce Biosciences: Small-cap rare endocrine biotech developing therapies for congenital adrenal hyperplasia and other endocrine disorders, closely comparable in indication focus and company stage.
Broad incumbents
- Tempest Therapeutics: Oncology-focused therapeutics company; based on co-mingled source content, Millendo's forward direction appears tied to Tempest, making it the most directly relevant current operating peer.
- Neurocrine Biosciences: Established mid-cap biopharma with deep endocrine and neurology franchises; provides a comparable commercialized benchmark for the rare-endocrine space Millendo historically addressed.
- Ipsen: Global specialty pharma with a meaningful rare endocrine and rare disease portfolio (e.g., Increlex for growth disorders) — sets the commercial bar for any rare-endocrine asset a small biotech like Millendo might develop.
Market position
Customer concentration
Millendo Therapeutics social profiles
Digital presenceMillendo Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Millendo Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Millendo Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Millendo Therapeutics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Millendo Therapeutics
What does Millendo Therapeutics do?
Millendo Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for endocrine diseases, with a particular focus on rare and underserved conditions such as adrenocortical carcinoma. The company has historically pursued drug candidates targeting endocrine disorders through its own pipeline development and corporate transactions.
When was Millendo Therapeutics founded?
Millendo Therapeutics was founded in 2011. It employs 11 to 50 people.
Where is Millendo Therapeutics based?
Millendo Therapeutics is headquartered in Ann Arbor, United States, in the North America region.
Who are Millendo Therapeutics's main competitors?
Direct peers on record are Corcept Therapeutics, Soleno Therapeutics, Crinetics Pharmaceuticals, Strongbridge Biopharma and Spruce Biosciences. Broad incumbents are Tempest Therapeutics, Neurocrine Biosciences and Ipsen.
Does Millendo Therapeutics have an API?
No public API is recorded for Millendo Therapeutics.
What industry is Millendo Therapeutics in?
Millendo Therapeutics's product category is Endocrine Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 3254 and its SIC code is 2834.